It is widely postulated that systemic inflammation related to lung infections is largely caused by cytokine translocation from the lungs into the systemic circulation but there is a paucity of animal models to evaluate this hypothesis. In this proof-of-concept study, we developed a murine model to determine whether interleukin (IL)-6, a primary inflammatory cytokine, translocates following airway exposure to endotoxin. We collected central venous blood from the right atrium and arterial blood from the aorta simultaneously at 4 h and 24 h following intratracheal exposure to endotoxin (25 mg) and measured IL-6 in the serum and broncho-alveolar lavage (BAL) fluid (n ¼ 33 mice). We repeated the experiment following 3 d of treatment with dexamethasone (n ¼ 31 mice). Without stimulation, there was no significant arteriovenous gradient (3 pg/ml with interquartile range [IQR] of 3-5 pg/ml in arterial versus 18 pg/ml with IQR of 8-24 pg/ml in venous serum; P ¼ 0.86). A significant arteriovenous difference was observed by 4 h post-exposure to endotoxin (2813 pg/ml with IQR of 1578-4316 pg/ml in arterial versus 1282 pg/ml with IQR of 778-2699 pg/ml in venous serum; P50.0001). The rise in the BAL IL-6 levels correlated with the increases in the arterial serum levels (P50.0001). Administration of intraperitoneal dexamethasone for 3 d attenuated the increased arteriovenous gradient. This murine model facilitates the estimation of cytokine translocation across the lungs and evaluation of compounds to modulate this gradient.
INTRODUCTION
Both acute (e.g. pneumonia and sepsis) and chronic inflammatory lung conditions (e.g. bronchiectasis and chronic obstructive pulmonary disease [COPD]) are commonly characterized by a systemic inflammatory process, which, in a dose-dependent fashion, causes extrapulmonary end-organ damage. [1] [2] [3] [4] In many cases, the systemic inflammatory response occurs in the absence of overt bacteremia and may progress even after the putative bacterial organisms have been fully treated. 4 It is assumed that the inflammatory focus in the lungs drives this systemic inflammatory process and, by controlling lung inflammation, systemic inflammation may also be abrogated. This notion is supported by human studies in which investigators have demonstrated a large gradient in inflammatory mediators such as interleukin (IL)-6 between the pulmonary and systemic arterial blood in critically ill patients with active lung disorders but not in patients without any over lung disease. 5 While powerful, these human data are limited owing to small sample sizes, heterogeneity of the underlying lung diseases, and the potential confounding effects of treatment including mechanical ventilation, antimicrobial agents, and surgery. An animal model (especially a murine one that would allow transgenic experiments in the future) would be desirable to evaluate better cytokine translocation related to lung inflammation and, importantly, determine whether it can be modulated using (potential) therapeutic compounds. To address this need, we developed a murine model using intratracheal endotoxin to: (i) quantify the magnitude of IL-6 translocation from the lungs into the systemic circulation; and (ii) determine whether or not pre-treatment with systemic or intratracheal glucocorticoids can down-regulate IL-6 translocation and thus attenuate systemic inflammation following endotoxin exposure as 'proof-of-concept'. Interleukin-6 was chosen as the biomarker in this study because it is intrinsically important in orchestrating both innate and adaptive immunity, is a potent inducer of acute phase proteins (such as C-reactive protein and fibrinogen), has been associated with morbidity and mortality in sepsis [6] [7] [8] [9] and other chronic inflammatory lung conditions involving infections 10 and may be modifiable with novel, emerging therapies. 11 
MATERIALS AND METHODS

Animal model
We used C57BL/6J male mice with an average weight of 25.76 AE 1.77 g (mean AE SD), which were purchased from Jackson Laboratory (Bar Harbor, ME, USA). All animals were 10-12 weeks old at the start of the experimental protocol and were maintained on a standard mouse chow and housed in a controlled environment with a 12-h light/dark cycle in an animal facility at St Paul's Hospital Vancouver, BC, Canada. This study was approved by the Animal Care Committee of the University of British Columbia.
Lipopolysaccharide and saline administration
The lipopolysaccharide (LPS) group of mice was anesthetized with isoflurane and underwent a short surgical procedure wherein a small neck incision was created to expose their trachea for instillation of 25 mg LPS (L2630; Sigma, St Louis, MO, USA) mixed in 100 ml of sterile saline using a 28-gauge needle. We chose a relatively low dose of LPS in order to induce lung inflammation without causing significant structural damage to the lung and to model various insults relevant for human disease (e.g. cigarette smoking and occupational exposures). [12] [13] [14] After the instillation, the incisional site was closed and the mice were allowed to recover from the anesthetic procedure. The saline group of animals was exposed to sterile saline (100 ml) only, using the same method. Because intratracheal instillation of saline may induce an inflammatory response, we also had a control group in which mice were not exposed to any intratracheal stimulation.
Surgical procedure to collect arterial and central venous blood simultaneously from mice
To determine the arteriovenous gradient of IL-6 across the lungs, (which in turn estimates IL-6 translocation from lungs into the systemic circulation), we collected blood from the right atrium (the source of central venous blood) and the ascending aorta (the source of arterial blood) simultaneously. At 2, 4, 8 and 24 h following the initial LPS instillation, respectively, the mice were anesthetized with isoflurane and restrained in a supine position. A midline abdominal incision was surgically created to expose the abdominal aorta. The mesentery was then dissected to expose the inferior vena cava (IVC). The IVC was punctured using a 24-gauge catheter needle (Protectiv Õ Plus, Medex, Lancashire, UK). The cutting needle was then removed retaining only the outer plastic cannula in the IVC. The cannula was then carefully threaded into the right atrium of the animal. We confirmed that the tip of the cannula was in the right atrium by visual inspection following sacrifice. Another similar catheter was inserted into the abdominal aorta and threaded upwards to the ascending aorta. Because the mouse heart is extremely small and delicate, we could not push the catheter beyond the tricuspid valve on the right side of the heart or the aortic valve on the left side of the heart. Once the two catheters were in the correct positions, blood was drawn from the catheters simultaneously ( Fig. 1 ). We used the same procedure to collect central venous and arterial blood in the saline exposed animals. We also performed broncho-alveolar Arterial blood lavage (BAL) just following blood collection at the 4-h and 24-h time points only (because it was associated with the largest arteriovenous gradient across the lungs) by instilling 1 ml of normal saline through the trachea. The BAL fluid (BALF) was then centrifuged (400 g, 4 C, 5 min) and the supernatants were collected.
Venous blood
Measurements of interleukin-6
The blood and BALF samples were centrifuged and separated into their components. From the serum, IL-6 was measured using a mouse-specific IL-6 enzymelinked immunosorbent assay (ELISA) kit (#12-MKL6-1; Alpha Diagnostics, Salem, NH, USA). All samples were measured twice and the coefficient of variation (CV%) of the venous IL-6 measurement was 1.79 AE 1.54% and that of the arterial measurements was 2.29 AE 2.07%. From the BALF, we also measured albumin (to evaluate vascular permeability and determine whether translocation occurred from the blood to the lungs).
Dexamethasone pretreatment
To determine whether or not glucocorticoids can attenuate the arteriovenous gradient of IL-6, we injected intraperitoneally dexamethasone (5 mg/g suspended in 50 ml of saline). In the second group, we slowly instilled 50 mg/g of dexamethasone (D2915; Sigma) suspended in 50 ml of saline into the nostril of mice. This was repeated once daily for 3 d prior to LPS or saline instillations. In the third group, we instilled saline (50 ml) using the same method once a day for 3 d. All of these instillations were performed while the mice were under light sedation using isoflurane. One hour following the last treatment of dexamethasone or saline, the LPS experiment described in the previous section was repeated and the arterial and venous IL-6 levels were determined.
Statistical analysis
Because the IL-6 data were non-normally distributed, we used a Wilcoxon rank sum test to compare IL-6 levels between the LPS and saline (or control) groups. A Wilcoxon signed rank test was used to compare arterial and venous IL-6 levels from the same mouse. When three groups were involved, we used a Kruskal-Wallis Rank Sum Test. To mitigate the risk of a type 1 error associated with multiple comparisons, we adjusted the P-value value for a false discovery rate. 15 A Spearman correlation and linear regression were used to explore the association between BALF IL-6 and serum IL-6. Data were analyzed using SAS v.9.1 (Carey, NC, USA) and R 2.3. Statistical significance was considered at P50.05 (two-tailed).
RESULTS
Time series experiments
A total of 84 mice were studied for this portion of the study to determine the arteriovenous gradient of IL-6 across the lungs. In 66 of these animals (79% success rate), we were able to collect approximately 100 ml of whole blood from the right atrium and aorta combined, making it possible to measure serum IL-6 levels from both the central venous and arterial samples. Success was largely contingent on the initial weight of the mice: 87% success rate in mice weighing 24 g or more versus 40% in mice weighing less than this threshold (P50.0001). The serum IL-6 levels in the central venous and arterial blood across different time points are summarized in Tables 1 and 2. In the control mice, which were not exposed to LPS or saline, the serum IL-6 levels were higher in the venous than in the arterial blood, though the P-value failed to reach statistical significance after adjustments for a false discovery rate. The median (interquartile range, IQR) of arterial IL-6 in the control mice was 3 pg/ml (2.7-4.9 pg/ml) whereas it was 18 pg/ml (8-24 pg/ml) in the venous blood (P ¼ 0.86). With LPS instillation, a significant arteriovenous difference in IL-6 occurred at 4 h and 8 h postexposure. With saline exposure, a significant arteriovenous difference was observed only at 4 h (Table 1) . At the 4-h time point, the arterial levels were on average over 9 times higher (P50.0001) and the venous levels were nearly 8 times higher in the LPS than in the saline group (P50.0001). However, at the 24-h time point, the arterial levels were only 2.5 times higher in the LPS than in the saline group (P ¼ 0.01), while the venous levels were similar between the two groups (P ¼ 0.84; Table 2 ).
Broncho-alveolar lavage fluid
Broncho-alveolar lavage fluid was collected in 33 animals at the 4-h and 24-h time points and these findings are summarized in Table 3 . Compared with saline exposed animals, LPS induced a significant rise in the BAL IL-6 expression at all time points. There was a significant correlation between BAL and serum IL-6 levels at 24 h (Fig. 2) . The Spearman correlation coefficient at 24 h was 0.632 (P ¼ 0.01). This association was most notable in the LPS group at 24 h (Spearman correlation coefficient at 24 h, À0.68; P ¼ 0.05) but not apparent in the saline group (Spearman correlation coefficient, À0.38; P ¼ 0.36). At 4 h post-installation, there was no correlation in the IL-6 levels between the BAL fluid and serum in either the LPS (Spearman correlation coefficient, 0.38; P ¼ 0.36) or the saline groups (Spearman correlation coefficient, À0.43; IL-6 translocation and systemic inflammation 253 P ¼ 0.30). However, when combined, the correlation became significant with a Spearman correlation of 0.610 (P ¼ 0.01), probably owing to increased sample size. Additionally, at the 4-h time period, we measured albumin in the BAL fluid. The group exposed to LPS had significantly higher albumin than the group exposed to saline (P ¼ 0.02; Fig. 3 ) suggesting increased vascular permeability with translocation of albumin (which is produced mostly by hepatocytes) from the systemic circulation into the lungs.
The effect of dexamethasone on the IL-6 arteriovenous gradient across the lungs
In this experiment, we used 31 mice. There were three groups: one treated with intra-nasal instillation of dexamethasone (intranasal steroids), the second treated with intraperitoneal injection of dexamethasone (intraperitoneal steroids) and the third treated with intranasal instillation of saline (saline group) for 3 d before exposure to LPS. Steroids attenuated the arteriovenous gradient of IL-6. The arteriovenous gradient was reduced with administration of dexamethasone (P ¼ 0.03 for global comparison; see Fig. 4A ). Intraperitoneal administration had the most significant effect in attenuating the arteriovenous difference in IL-6 (P ¼ 0.001). There were no significant differences in the arteriovenous gradient between the intranasal and intraperitoneal steroid groups (P ¼ 0.94) and a trend towards a lower Table 1 . A comparison of serum IL-6 levels between venous (blood taken from the right atrium) and arterial (blood taken from aorta) at each time interval following intratracheal instillation of LPS or saline arteriovenous value in the intranasal steroid group compared with intranasal saline group, though it did not reach statistical significance owing to the increased variability in the data. This was likely because, with intranasal administration, the animals frequently coughed up or aspirated the steroids, causing variable deposition of steroid particles in the lungs. Indeed, we estimated that less than 10% of the intranasal dose made it into the lungs. The difference in the arteriovenous gradient with steroids was driven largely by changes in the arterial expression of IL-6 (see Fig. 4B,C) . Dexamethasone significantly reduced the arterial, but not venous, concentrations of IL-6 (P ¼ 0.02 for global comparison in the arterial blood whereas P ¼ 0.69 for global comparison in the venous blood). These data suggest that the excess IL-6 in the arterial circulation is likely derived from the lungs and that glucocorticoids may be able to attenuate IL-6 spillage.
DISCUSSION
The systemic response induced by a focal inflammatory infection is an integral component of the innate immune response. 16 If excessive, this systemic inflammatory response has detrimental downstream effects on distant organ systems. 17 In this study, we used a model of acute lung inflammation (induced by LPS) to quantify the systemic response (using IL-6 as a surrogate marker) and determine the contribution of inflammatory mediators produced locally in the lung, to the systemic response. There were three notable findings in the present study. First, following intratracheal LPS stimulation, we found that IL-6, a primary regulator of the inflammatory process, translocated into the systemic circulation from the lungs. Interestingly, we found that even normal saline instillation induced an IL-6 gradient, suggesting that saline alone may provoke an inflammatory response in the lungs, an effect that has been observed in other organs and with hypertonic saline. 18, 19 In the control mice (which were not exposed to either LPS or saline), there were no significant differences between the arterial and venous IL-6 levels. However, we cannot fully discount the possibility that the neck incisional process may have contributed to the difference in arteriovenous levels of IL-6 in the LPS and saline-exposed animals. Second, we found that albumin, which is predominantly synthesized in the liver, translocated from the systemic circulation into the airways with LPS stimulation. Third, intraperitoneal treatment with dexamethasone attenuated the arteriovenous difference in IL-6 in this model. Interestingly, dexamethasone given intraperitoneally reduced arterial, but not venous, levels of IL-6 suggesting that steroids reduce systemic inflammation by attenuating lung inflammation (and lung permeability). Although we observed a similar magnitude of effect with the intranasal administration, it failed to reach statistical significance owing to the large variability in response to intranasal dexamethasone. This probably occurred because the drug were frequently aspirated or coughed up following intranasal administration. Collectively, these data suggest that, with inhalational exposure to LPS, the lungs become major producers of IL-6 (and most likely other inflammatory mediators), which in turn translocates into the blood-stream inciting a systemic inflammatory response. Glucocorticoids, on the other hand, can down-regulate this systemic inflammatory response when given prior to the insult possibly by reducing lung translocation of IL-6. As we did not directly measure IL-6 translocation, we cannot fully discount other potential mechanisms for the arteriovenous difference in IL-6 (e.g. intracellular secretion of IL-6 by circulating white blood cells). However, the contribution of IL-6 from other sources is likely to be quite small. Abbreviation: BAL, broncho-alveolar lavage; L, lipopolysaccharideexposed animals; N, normal saline exposed animals; IL, interleukin. All data expressed in pg/ml. P ¼ 0.01 for the correlation. It is now well known that with both acute and chronic lung injury, systemic inflammation ensues. 17 However, the mechanisms linking lung with systemic inflammation remain controversial. Some have suggested that inhalational toxins such as LPS and air pollution particles translocate and directly cause systemic inflammation by stimulating circulating leukocytes and hepatocytes to produce acute phase reactants. 20 However, there is mounting evidence from both animal and clinical studies to suggest that most of inhaled particles are phagocytosed by inflammatory cells and are cleared in the lungs and that very little, if any, spills into the systemic circulation. 21, 22 Another plausible theory is that inhaled particles do not translocate significantly but induce lung inflammation, which, in turn, spills into the systemic circulation inciting a systemic inflammatory response. Despite the intuitive appeal of this hypothesis, to date, there has been little animal evidence to support it. We developed this animal model that allows us to obtain blood from the right side of the heart and aorta simultaneously, and estimate the extent of IL-6 translocation in this murine model. We showed significant spillage of IL-6 from lungs into the systemic circulation, supporting the notion that lungs are the major drivers of systemic inflammation following acute lung injury with LPS. These observations are consistent with data reported by Tyburski et al., 5 who showed that serum IL-6 levels in radial arterial blood were 37% higher than those in mixed venous blood (taken from a pulmonary artery) in patients with active lung disorder such as pneumonia. In contrast, the arteriovenous difference of IL-6 was nearly zero in patients without any overt lung disease. 5 Thus, our murine model is likely to have relevance and applicability in studying the complex interaction of lung and lung-systemic inflammation in humans related to infectious agents, and other inhaled stimuli such as air pollution particulate. We chose LPS or endotoxin, a component of the outer envelope of pathogenic Gram-negative bacteria in the airways, 23 because it generates a predictable inflammatory response in the lung and its clinical relevance. It is known, for example, that with significant inhalation of Gram-negative bacterial organisms, LPS binds to soluble and membrane bound proteins of inflammatory as well as resident cells in the airway, which in turn causes activation of pattern-recognizing Toll-like receptor (e.g. TLR4) and initiates an IL-1 receptor signaling cascade that ultimately leads to the transcription of inflammatory and immune-response genes. 24 Interestingly, several workers have shown that plasma levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-a) and IL-6 rise in response to inhalational challenges with LPS in the absence of LPS translocation to the systemic circulation. 24, 25 Concurrent administration of inhaled glucocorticoids, on the other hand, attenuates this systemic inflammatory response to LPS. 26 We chose IL-6 as the 'inflammatory' end-point in the present study because it is an important early acute phase cytokine that orchestrates the down-stream inflammatory cascade, is known to be produced in the lungs, and is modifiable by glucocorticoids. 27 More importantly, it is a significant mediator of systemic inflammation and its systemic over-expression has been associated with increased morbidity and mortality (especially those pertaining to cardiovascular events). 28 Because mice are extremely small animals with very small circulatory volume, we were not able to acquire sufficient volumes to measure other cytokines except for IL-6 and TNF-a. However, TNF-a levels were not detectable likely because of the low dose of LPS used in this model (data not shown). It is also notable that, in mice not exposed to any tracheal stimulation, the venous IL-6 levels were higher than the arterial levels. With instillation of normal saline, arterial (but not venous) IL-6 levels increased causing a reversal in the arteriovenous gradient.
There were limitations to the present study. We did not obtain venous blood from the pulmonary artery because we could not push the catheter beyond the right atrium without significantly perturbing the integrity of the heart and thus we did not obtain blood in the pulmonary arteries. It is possible that some of the arteriovenous gradient of IL-6 may have been derived from the right ventricular myocardium or the pulmonary artery. The BAL IL-6 levels were, however, more than 4-fold higher than the serum levels and correlated significantly with arterial IL-6 in the LPS-stimulated mice (Fig. 1) , providing indirect evidence that most of the 'excess' IL-6 in aortic blood arose from the lungs (and not from the myocardium or pulmonary artery). Second, we did not measure inflammatory mediators other than IL-6 and additional studies will be required to determine which other mediators produced in the lung also translocate into the blood-stream. Third, we did not determine any downstream consequences of systemic inflammation in our model. However, the effects of IL-6 on extrapulmonary organs and endothelial function have been well described previously. [29] [30] [31] [32] We suspect that a major source of IL-6 production in the lungs is the alveolar macrophages. In previous experiments in our laboratory using rabbits, we found that the predominant source of IL-6 in the lung was alveolar macrophages and, to a lesser extent, airway epithelial cells. 33 We also showed that these two cell types interacted synergistically to mount a vigorous inflammatory response against inhaled stimulants. 34 CONCLUSIONS Using a murine model, we have demonstrated that LPS causes lung inflammation, which in turn contributes significantly to systemic inflammation through translocation of inflammatory molecules. Glucocorticoids can down-regulate the systemic inflammatory process by reducing the arteriovenous gradient of IL-6. Interestingly, significant differences in IL-6 between saline and dexamethasone were only detectable in arterial, but not venous, blood. These data raise the possibility that the effects of anti-inflammatory compounds on inflammatory mediators (biomarkers) following lung injury are best detectable in arterial (and not venous) blood. This may have implications in biomarker discovery, since most clinical studies collect venous, and not arterial, blood. Clinical studies are needed to validate these observations in mice.
